Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Benefits of the anticlotting drug “clearly outweigh the risks” for most patients, Lilly’s Paul says at R&D day.